Summary of clinical trial methodology
Study | Device Used | Time since Stroke-Symptom Onset | Vessels | IV tPA | IA tPA |
---|---|---|---|---|---|
SWIFT19a | Solitaire FR (Covidien, Irvine, California); Merci Retriever (Concentric Medical, Mountain View, California) | <8 hr | Large-vessel occlusion | Contraindicated or failed | Excluded |
ESCAPE20b | Any approved neurothrombectomy device | <12 hr | Large-vessel occlusion | Yes | Unspecified |
REVASCAT21c | Solitaire FR | <8 hr | Anterior circulation occlusion | Yes | Allowed |
EXTEND IA22d | Solitaire FR | <4.5 hr | Anterior circulation occlusion | Yes | Unspecified |
DAWN23e | Trevo retriever (Stryker, Kalamazoo, Michigan) | 6–24 hr | Anterior circulation occlusion | Contraindicated or failed | Excluded |
MR RESCUE24f | Merci or Penumbra System (Penumbra, Alameda, California) | <8 hr | Large-vessel occlusion | Yes | Allowed |
THRACE25g | Any approved neurothrombectomy device | <5 hr | Large-vessel occlusion | Yes | Allowed |
Note:—IA indicates intra-arterial.
a Solitaire With the Intention For Thrombectomy (SWIFT).
↵b Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke (ESCAPE).
↵c Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours (REVASCAT).
↵d Extending the Time for Thrombolysis in Emergency Neurological Deficits—Intra-Arterial (EXTEND-IA).
↵e Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo (DAWN).
↵f Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy (MR RESCUE).
↵g Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke (THRACE).